Patent intelligence · US
US 6319691
Fusion proteins comprising IFN-alpha2b and TM-alpha1
Fusion proteins comprising IFN-alpha2b and TM-alpha1
Patent details — US 6319691
- Jurisdiction
- US
- Status
- expired
- Grant date
- Nov 20, 2001
- Expiration
- Nov 15, 2021
- Applicant
- USA Universe Bioengineering, Inc.
- Claims
- 4
- CPC classes
- A61K, A61K38/00
Quick answer
US 6319691 (Fusion proteins comprising IFN-alpha2b and TM-alpha1) is held by USA Universe Bioengineering, Inc.. Status: expired. Granted Nov 20, 2001. Expires Nov 15, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- USA Universe Bioengineering, Inc.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K38/00
More from USA Universe Bioengineering, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 6319691?
US 6319691 (Fusion proteins comprising IFN-alpha2b and TM-alpha1) is held by USA Universe Bioengineering, Inc.. Status: expired. Granted Nov 20, 2001. Expires Nov 15, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6319691?
USA Universe Bioengineering, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 6319691 expire?
Our index shows an expiration date of Nov 15, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.